Fig. 4From: Verification of B-lymphocyte activating factor’s involvement in the exacerbation of insulin resistance as well as an autoimmune response in patients with nonalcoholic steatohepatitis and patients with HCV-related chronic liver diseaseRelationship between serum BAFF levels and insulin resistance in patients with NASH (a) and patients with CLD-C (b). BAFF B-lymphocyte activating factor, NASH nonalcoholic steatohepatitis, CLD-C HCV-related chronic liver disease, HOMA-IR homeostasis model for assessment of insulin resistanceBack to article page